Abstract: Nucleic acids are described that encode for triggering receptor expressed on myeloid cells 2 (TREM2) and that can be used in expression constructs, vectors and gene therapies. Also described are methods of using the same for the treatment of TREM2-associated diseases and disorders, especially neurological diseases such as Alzheimer's Disease (AD), Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) or Nasu-Hakola Disease (NHD).

Abstract: The present invention relates to a promoter sequence for efficient and sufficient expression of transgenes as well as to gene transfer vectors comprising said promoter sequence for use in therapy. In particular, the present invention relates to lentiviral vectors that provide gene therapy for pathological conditions of the central nervous system.

Abstract: Provided herein are gene therapy methods, vectors and constructs for the treatment of Duchenne Muscular Dystrophy in a subject.

Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.

Abstract: The present disclosure provides compositions and methods for the treatment of ocular diseases associated with angiogenesis, particularly wet age-related macular degeneration.

Abstract: Embodiments herein describe systems and methods to enhance RNA stability and uses thereof. Many embodiments alter the sequence of an RNA therapeutic molecule (e.g., vaccines) to encode for a variant peptide while maintaining and/or increasing stability of the RNA therapeutic.

Abstract: Disclosed herein are compositions comprising one or more subgenomic Flavivirus RNA (sfRNA) elements and using those compositions in methods of improving mRNA transcript stability, improving mRNA transcript translation efficiency, enhancing gene therapy, and treating and/or preventing a disease or disorder.

Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting modulating or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.

Abstract: The present invention refers to the medical field. Particularly, it refers to a method for determining whether an immune response has occurred in subjects who have been infected with- or vaccinated against coronavirus.

Abstract: A dispersion for an X-ray target in which gold nanoparticles and sodium alginate or a calcium phosphate-based bone reinforcing material are dispersed, in which the gold nanoparticles are in contact with the sodium alginate or the calcium phosphate-based bone reinforcing material.

Abstract: The present disclosure provides compositions and methods for reactive oxygen species imaging agents. Compositions include a reactive oxygen species (ROS) imaging agent according to any one of Formulas (I-VI)a and (I-VII)b. Methods of detecting ROS in a subject include administering to the subject an effective amount of a composition comprising a reactive oxygen species (ROS) imaging agent according to any one of Formulas (I-VI)a and (I-VII)b, and exposing the subject to an imaging modality such as PET or CT. Administering the composition comprising the ROS imaging agent results in penetration of the ROS imaging agent into a membrane, oxidation of the ROS imaging 10 agent by ROS, and trapping of the ROS imaging agent in a cell membrane and intracellular compartments.

Abstract: Described herein are radiotherapeutics that target tumor cells expressing the neuropeptide Y1 receptor (NPY1R) and their use in the treatment and/or diagnosis of cancer.

Abstract: The present invention relates to a nucleic acid nanostructure comprising one or more, preferably at least two, targeting agent(s) and a plurality of dye molecules, preferably at least to dye molecules. The present invention further relates to a composition, preferably pharmaceutical composition, comprising a nucleic acid nanostructure. The present invention also relates to a nanostructure or composition for use in medicine, preferably for use in medical imaging, and for use in a method of preventing, treating, and/or diagnosing a disease. Furthermore, the present invention relates to a method of labelling a target in a sample, to the use of a nanostructure as a stain, and to a kit. Moreover, the present invention further relates to a method of preparing a nanostructure.

Abstract: Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface calreticulin, alone or in combination with other therapies, are provided. The radiolabeled calreticulin targeting agent delivers radiation to cells that externally present calreticulin, such as tumor cells, depleting those cells and neighboring malignant cells to effect overall tumor reduction. Radiation delivered by the radiolabeled calreticulin targeting agent itself increases the cell surface expression of calreticulin, leading to a feed-forward mechanism that drives further accumulation of the calreticulin targeting agent at target lesions to enhance its therapeutic effect. Since cell surface expression of calreticulin is upregulated in response to cell damage and stress, radiolabeled calreticulin targeting agents may also be used in combination with other anticancer therapies to amplify their efficacy.

Abstract: The application describes a T-cell expressing a chimeric antigen receptor (‘CAR T-cell’) containing superparamagnetic iron-based particles (‘loaded CAR T-cell’) for use in treating a tumor. Said loaded CAR T-cell exhibits a reduced cytokine release upon binding to a cell of the tumor expressing an antigen being recognized by the CAR of the CAR T-cell, compared to a CAR T-cell not containing superparamagnetic iron-based particles (‘unloaded CAR T-cell’) under the same conditions. Furthermore, an in vitro method of generating a CAR T-cell containing superparamagnetic iron-based particles is described, whereby such loaded CAR T-cells are generated.

Abstract: The present invention relates to a 215- to 222-nm wavelength laser light generating device comprising: an excitation light source part for converting a laser light with a wavelength of 1030 to 1064 nm to a second harmonic, and generating a laser light with a wavelength of 515 to 532 nm; an optical parametric oscillating part for generating a signal light with a wavelength of 858 to 887 nm and an idler light with a wavelength of 1288 to 1330 nm using the laser light with the wavelength of 515 to 532 nm as an excitation light; a separating part for separating the signal light and the idler light; a first wavelength converting part for generating a fourth harmonic from the signal light; a second wavelength converting part for generating a deep ultraviolet light with a wavelength of 215 to 222 nm by sum frequency with a second harmonic of the excitation light from the idler light; and a coupling part for coupling the fourth harmonic from the first wavelength converting part and the deep ultraviolet light from the

Abstract: The present invention relates to a 399.08-nm wavelength ultraviolet laser light generating device, comprising: an excitation light source part for converting a 1064.2-nm laser light to a second harmonic, and generating a 532.1-nm laser light; an optical parametric oscillating part for generating a 798.15-nm signal light and a 1596.3-nm idler light using the 532.1-nm laser light; a first wavelength converting part for generating a 399.08-nm light by sum frequency generation of the 1596.3 nm idler light and a 532.1-nm light; and a second wavelength converting part for generating a 399.08-nm light of a second harmonic from the 798.15-nm signal light. The order of the first wavelength converting part and the second wavelength converting part is random. The present invention relates to a 228.04-nm wavelength ultraviolet laser light generating device comprising the 399.08-nm wavelength laser light generating device and a third wavelength converting part for subjecting a 399.08-nm light and a 532.

Abstract: Provided herein is a skin preparation device having a container having a proximal end, a distal end, and a sidewall therebetween, defining an interior, a disinfecting solution received within the interior, and an applicator arranged at the distal end of the container, the applicator in fluid communication with the interior of the container.

Abstract: A disinfection device for disinfecting a hub of a medical device includes a housing having a first end and a second end, a power source, an ultraviolet light source, and a connection mechanism located at the first end of the housing, wherein connection of the hub of the medical device to the disinfection device initiates a disinfection process configured to disinfect the hub. the ultraviolet source may be a light emitting diode with a peak of wavelength within the range of 100-400 nm (specific implementations being 225-264 nm) and the connection mechanism includes one or more of a screw thread, a channel, ridge, a friction fit connector, a magnet, or a ferromagnetic material. The disinfection device may include a port located on the second end, wherein the one or more port is configured for coupling to an external device and receiving a charge or power supply from the external device.

Abstract: A disinfection system can include a console and an operably connected disinfection unit. The console can have electronic circuitry including memory with executable instructions configured to cause the console to perform various processes when executed by one or more processors of the console. The various processes can include characterizing with medical-device characterization logic characteristics of at least an elongate portion of a medical device for establishing or maintaining vascular access in a patient. The various processes can also include determining with disinfection logic a disinfection profile for disinfecting at least the elongate portion of the medical device with ultraviolet (“UV”) light. The disinfection unit can include a disinfection compartment suitably sized to enclose the medical device therein.

Abstract: A disinfecting device having a housing and an ultraviolet source located in the housing. The disinfecting device may include a tube that includes a first end connected to the housing and a second end free of the housing. An end cap may be located at the second end of the tube. In use, ultraviolet light may be emitted from the ultraviolet source and propagated to the end cap in order to disinfect a portion of a medical device.

Abstract: A system or device configured to disinfect an appliance may include at least one or more light emitters configured to emit disinfecting light. The system may be further configured to direct the disinfecting light to illuminate a surface of an appliance.

Abstract: A sanitization system for an aircraft may comprise: a power source; and a plurality of sanitizers in electrical communication with the power source, each sanitizer in the plurality of sanitizers configured to emit ultraviolet radiation having an average wavelength between 200 and 230 nm, the power source configured to provide power to each sanitizer in the plurality of sanitizers in succession during an occupied flight of the aircraft.

Abstract: An active plasma sterilizer (APS) system for sterilization/decontamination is provided, including a sterilization box and a plurality of compact portable plasma reactors (CPPRs) disposed in the sterilization box and configured for generating surface dielectric barrier discharge (SDBD) for generating and distributing reactive oxygen and nitrogen species (RONS) such as ozone. Each of the plurality of CPPRs includes a reactor panel and a power supply circuit. The reactor panel includes one or more electrodes separated by a dielectric medium. The active plasma sterilizer (APS) system may include an ozone decomposition module having a heating element connected to a power supply and configured to decompose ozone by heating ozonated air; a power supply module for supplying power to the heating element; connecting pipes for providing paths for ozonated air to travel through; and an air pump configured to circulate the ozonated air generated.

Abstract: Provided herein is a disinfecting device, including a housing having a proximal end, a distal end having an opening therein, and a sidewall therebetween defining an interior in fluid communication with the opening, one or more flanges arranged at the distal end of the housing, and a disinfecting solution received within the interior, wherein the sidewall includes a deformable portion adjacent the distal end.

Abstract: The invention discloses a method for cleaning or sanitization of an affinity chromatography matrix, comprising the steps of: a) providing an affinity chromatography matrix having oxidation-tolerant proteinaceous ligands coupled to a support, b) contacting the matrix with a sanitization solution comprising at least one oxidant defined by formula I, wherein R is hydrogen or an acyl group R?—C(O)—, with R? being a hydrogen or a methyl, ethyl or propyl group.

Abstract: Embodiments of the present disclosure relate to an oxygen cleaning chamber with UV radiation generator temperature control and a method of atomic oxygen cleaning a substrate. The atomic oxygen cleaning chamber includes a process chamber and a cooling chamber coupled to the process chamber and a divider sealingly separating the process chamber from the cooling chamber. An ultraviolet (UV) radiation generator is disposed in the cooling chamber and provides UV radiation through the divider into the process chamber. A gas distribution assembly distributes ozone over an upper surface of a pedestal in the process chamber and a coolant distribution assembly distributes cooling gas into the cooling chamber to cool the UV radiation generator. By actively cooling the UV radiation generator, a higher intensity UV radiation at a stable wavelength is produced, i.e., without wavelength drift normally associated with high power UV radiation generator outputs.

Abstract: A device and system automatically release scents in an immersive environment. When an audio signal includes a sound associated with an event correlated to one of the scents, the device releases the scent to provide the improved immersive experience with the sense of smell included in the scene. The occurrence of an event may be predicted by an artificial intelligence engine. The artificial intelligence engine may determine when an event associated with a scent to be dispensed is going to occur so that the timing of the dispense is more accurate and correlated with the timing of the action in the audio signal.

Abstract: The invention relates to a device and method for dispensing volatile substances, in particular fragrances and/or active ingredients, and comprises a housing (2), a container (5) for the substance (6) to be dispensed and a wick (18) as capillary element which is in contact with the substance (6) to be dispensed and which has a wick-side substance-dispensing region (20). According to the invention the device (1) has a temperature measuring device for direct or indirect measurement of the wick temperature (TD) at the wick-side substance-dispensing region (20), having at least one temperature sensor (13, 14) and having a measuring value output at which, during operation, an electrical wick temperature measuring signal corresponding to the currently measured wick temperature (TD) is supplied. The device (1) has furthermore an open-loop control device or a closed-loop control device for controlling the wick temperature (TD) at the wick-side substance dispensing region (20).

Abstract: The present technology presents an apparatus for cleaning the air and surfaces within an enclosed space of a viral, microbial, or malodor contamination. In an exemplary embodiment, the apparatus includes: a container configured to contain a water and a solid or gel pack that releases the gaseous cleaning agent upon contact with the water; an aerator housed in the base of the container; an air distributor in the container configured to distribute air from the aerator into the container to cause agitation of the water and release of gaseous agent; and a lid on the container having an opening configured to accelerate an air-borne spray of gaseous agent and water droplets therethrough into the surroundings.

Abstract: A mechanical system for reproducing scents includes the following: a container housing a scent; a pump for pumping the scent; a switch for selectively activating the pump; a mixer or evaporator for receiving the scent from the pump and transforming the scent into a vapor; and a media device configured to communicate with the switch for selective activation thereof.

Abstract: A method of controlling vapor emissions using a liquid vapor trap containing an effective amount of a barrier fluid that will greatly reduce the volume of noxious and/or other gases emitted from a containment (natural or man-made) into the atmosphere. Examples of containment include, but are not limited to septic, fossil fuels and landfills.

Abstract: A method of controlling vapor emissions using a liquid vapor trap containing an effective amount of a barrier fluid that will greatly reduce the volume of noxious and/or other gases emitted from a containment (natural or man-made) into the atmosphere. Examples of containment include, but are not limited to septic, fossil fuels and landfills.

Abstract: Disclosed herein is a mobile sterilization and disinfection system configured to operate under official requirements for the handling of BIHW, adapted to perform the indicated procedures at the place where such wastes or residues are generated, increasing the efficiency of the processes to achieve it and ensuring that the pre-established routes for its transfer do not constitute an additional risk for the persons in charge of the handling. The operation and increased efficiency of the mobile system is a function of temperature diffusion control during the sterilization cycles, as well as joint and system-specific conditions to achieve increased efficiency.

Abstract: The present invention relates to the use of hydrogel in the treatment of pressure ulcers and/or in the prevention of the formation of pressure ulcers, particularly of pressure ulcers caused by devices or by medicinal products.

Abstract: Described herein are embodiments of a wound dressing layer. The wound dressing layer may include an open-cell foam. The foam may have a 50% compression force deflection of not more than about 4.8 kPa. The foam may also have a density of at least 24 kg/m3. The foam may exhibit a density increase of a factor of at least 12 at about ?75 mmHg.

Abstract: The present disclosure provides an anti-adhesion composition for wound protection in the form of a film comprising a biocompatible mucoadhesive polymer and a specific swellable polymer. The present disclosure relates to an anti-adhesion agent that is flexible and adheres appropriately to an application site by improving crumbling and adhesion properties, which are problems of existing film-type anti-adhesion agents.

Abstract: A composition including: (a) one or more alkyl acrylaor alkyl methacrylate based polymer film forming agents; (b) one or more (C1-C6)alkyl N(alpha)-(C10-C25)alkanoyl-L-arginate disinfectant or a salt thereof; (c) a solvent system comprising: (c1) one or more water immiscible solvents selected from (C1-C5)alkyl-CO—O—(C1-C6)alkyl, ((C1-C6)alkyl)3Si—O-Si((C1-C6)alkyl)3, (C1-C5)alkyl-O—(C2-C5)alkyl and a mixture thereof; (c2) acetone; and (c3) one or more (C2-C3) alcohols and processes for its preparation. An adherent film, including: (a) one or more film forming agents; and (b) one or more disinfectants; and processes for its preparation.

Abstract: The present invention relates to a soft tissue adhesive comprising an aqueous composition comprising ?-TCP and a phosphorylated amino acid. The composition has improved mechanical strength and is casily applied to the tissue.

Abstract: The present invention provides radioactive glass microspheres for embolization and a preparation method and an application thereof. A nuclide oxide and a foaming agent are added into a glass matrix, blended and uniformly mixed for making the foaming agent decomposed and vaporized at a high temperature to generate bubbles, so as to prepare the radioactive glass microspheres for embolization with cavities. The radioactive glass microspheres for embolization have a density of 1.4-2.3 g/cm3, a nuclide loading rate of 15-40 wt % and a higher and more stable radiation dose, can achieve better distribution and deposition effects in liver blood vessels after injection, and can achieve a better therapeutic effect for hepatocellular carcinoma (HCC).

Abstract: The presently-disclosed subject matter includes hydrophilic thioketal polymers and scaffolds formed therefrom.

Abstract: Non-woven graft materials for use in specialized surgical procedures such as neurosurgical procedures, methods for making the non-woven graft materials, and methods for repairing tissue such as neurological tissue using the non-woven graft materials are disclosed. More particularly, disclosed are non-woven graft materials including at least two distinct fiber compositions composed of different polymeric materials, methods for making the non-woven graft materials and methods for repairing tissue in an individual in need thereof using the non-woven graft materials.

Abstract: Disclosed herein are polyurethane polymer matrices with a porosity of from about 20 microns to about 90 microns that are useful in promoting closure and protection of incision sites; supporting the lower pole position of breast implants; and providing a partial or complete covering of breast implants to provide a beneficial interface with host tissue and to reduce the potential for malpositioning or capsular contracture. The disclosed matrices can be seeded with mammalian cells.

Abstract: Tissue product compositions and methods for treating a patient are provided. The tissue product composition may include a flowable carrier including a hyaluronic acid based material and acellular tissue matrix particles mixed within the carrier. Methods of producing the tissue product composition and an injection device filled with the tissue product composition are also provided.

Abstract: The present invention relates to a transdermal photocuring forming hydrogel with biological activity. The hydrogel can release recombinant collagen with biological activity, the recombinant collagen includes a sequence as shown in SEQ ID No. 1, an amino acid sequence of the recombinant collagen includes N basic repetitive units, and each basic repetitive unit includes n1 of the following characteristic amino acid sequences: “G-Xaa1-Xaa2-G-E-Xaa3”; the 3? end and the 5? end of the basic repetitive unit are connected to form the above characteristic amino acid sequence. The recombinant collagen provided by the present invention has relatively obvious integrin binding activity, and has the effects of promoting cell adhesion, proliferation and differentiation. The hydrogel of the present invention has good biocompatibility and stable quality, which can be cured and formed in situ in a transdermal photo-crosslinking manner after injection, with simple, convenient and controllable operation.

Abstract: The present invention relates to silk fibroin bioinks specifically formulated for use in 3D bioprinting and the production of ex-vivo models capable of supporting hematopoiesis and the production of platelets and blood cells.

Abstract: This invention provides solid substrates for promoting cell or tissue growth or restored function, which solid substrate is characterized by a specific fluid uptake capacity value of at least 75%, which specific fluid uptake capacity value is determined by establishing a spontaneous fluid uptake value divided by a total fluid uptake value. This invention also provides solid substrates for promoting cell or tissue growth or restored function, which solid substrate is characterized by having a contact angle value of less than 60 degrees, when in contact with a fluid. This invention also provides solid substrates for promoting cell or tissue growth or restored function, which said substrate is characterized by a substantial surface roughness (Ra) as measured by scanning electron microscopy or atomic force microscopy. The invention also provides for processes for selection of an optimized coral-based solid substrate for promoting cell or tissue growth or restored function and applications of the same.

Abstract: Some embodiments of the disclosure provide a decellularized heart valve (DHV) composite, a preparation method of the DHV composite, and a use of the DHV composite. In some examples, the preparation method of the DHV composite includes the following steps: S1, conducting a reaction I on a DHV with a copper chloride-dopamine hydrochloride mixed solution to obtain a copper ion-modified DHV; and S2, conducting a reaction II on the copper ion-modified DHV with a GDF11 solution to obtain the DHV composite. In other examples, the present disclosure provides a use of the DHV composite in preparation of a tissue-engineered heart valve (TEHV). In further examples, the TEHV is a heart valve (HV) with remodeling and regeneration capabilities.

Abstract: The invention is directed to a porous osteoinductive composite comprising osteoinductive granules embedded in a porous matrix, wherein more than 5% of the surface area of the osteoinductive granules is exposed from said matrix as determined by scanning electron microscopy (SEM) imaging. Such a composite can suitably be used in a medical treatment, for example in a medical treatment of connective tissue and/or bone loss or defect.

Abstract: Provided is a surface treatment method for a surgical implant that improves fatigue strength of the surgical implant while maintaining the microscopic surface structure of the surgical implant. A surface treatment method for a surgical implant, including: placing an additive manufactured surgical implant in a processing liquid, the surgical implant including a microscopic surface structure having a complete penetration area and an incomplete penetration area; and causing a nozzle immersed in the processing liquid to eject a cavitation jet of the processing liquid to the surgical implant to remove the incomplete penetration area remaining on a surface of the surgical implant and apply a compressive residual stress to the surface of the surgical implant.